CAS 1362850-20-1

Seletalisib

CAS: 1362850-20-1

Seletalisib

Fórmula: C₂₃H₁₄ClF₃N₆O

Pureza: ≥95%

Peso molecular: 482.85

Ref: 54-BUP04946

(R)-3-(8-Chloro-3-(2,2,2-Trifluoro-1-(Pyrido[3,2-D]Pyrimidin-4-Ylamino)Ethyl)Quinolin-2-Yl)Pyridine 1-Oxide

CAS: 1362850-20-1

(R)-3-(8-Chloro-3-(2,2,2-Trifluoro-1-(Pyrido[3,2-D]Pyrimidin-4-Ylamino)Ethyl)Quinolin-2-Yl)Pyridine 1-Oxide

Fórmula: C₂₃H₁₄ClF₃N₆O

Pureza: 98+%

Peso molecular: 482.85

Ref: 54-PC108594

Seletalisib

CAS: 1362850-20-1

Seletalisib (UCB5857) (UCB5857) is a potent and specific PI3Kδ inhibitor (IC50: 12 nM).

Fórmula: C₂₃H₁₄ClF₃N₆O

Pureza: 99.81%

Cor e Forma: Solid

Peso molecular: 482.85

Ref: TM-TQ0044

Seletalisib

CAS: 1362850-20-1

(R)-3-(8-Chloro-3-(2,2,2-trifluoro-1-(pyrido[3,2-d]pyrimidin-4-ylamino)ethyl)quinolin-2-yl)pyridine 1-oxide

Fórmula: C₂₃H₁₄ClF₃N₆O

Pureza: 98+%

Peso molecular: 482.85

Ref: IN-DG766540

Seletalisib

CAS: 1362850-20-1

Pureza: 98.88%

Peso molecular: 482.85

Ref: 10-F979167

Seletalisib (UCB-5857)

CAS: 1362850-20-1

Seletalisib is a novel, potent, and selective inhibitor of the lipid kinase activity. It blocks protein synthesis by binding to the ribosomal protein S6 kinase-1 (RSK1) which is involved in regulating cell proliferation and differentiation. Seletalisib has been shown to be effective in clinical studies for treatment of autoimmune diseases such as systemic lupus erythematosus (SLE). This drug also has pharmacokinetic properties that are suitable for hepatic impairment. Seletalisib also inhibits the production of chemokines, which are inflammatory cytokines that induce chemotaxis of leukocytes and promote inflammation.

Fórmula: C₂₃H₁₄ClF₃N₆O

Pureza: Min. 95%

Peso molecular: 482.85 g/mol

Ref: 3D-MEC85020

Seletalisib

CAS: 1362850-20-1

Fórmula: C₂₃H₁₄ClF₃N₆O

Pureza: %

Cor e Forma: Solid

Peso molecular: 482.8451

Ref: IN-DA01EOAJ